SCHEMBL4579997

SCHEMBL4579997

O=C(NC1CC1)c1ccc2cncc(-c3ccc(C(=O)O)s3)c2n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.41
NPC1 O15118 1/20 0.41
TP53 P04637 1/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HSD17B10 Q99714 1/20 0.41
PIM1 P11309 1/20 0.39
CCNC P24863 6/20 0.39
CDK8 P49336 6/20 0.39
DYRK1A Q13627 1/20 0.39
DYRK1B Q9Y463 1/20 0.39
MAPK11 Q15759 6/20 0.37
MAPK14 Q16539 6/20 0.37
MAPK13 O15264 5/20 0.37
MAPK12 P53778 5/20 0.37
ESR1 P03372 1/20 0.37
ESRRG P62508 1/20 0.37
ESR2 Q92731 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4580001 0.84 CCNC (0.51) KDM4ENPC1HPGDRAB9ACCNC
SCHEMBL4579213 0.84 CCNC (0.48) KDM4ENPC1HPGDRAB9ASMN1; SMN2
SCHEMBL4580728 0.83 AKT3 (0.46) KDM4ENPC1TP53MAPTHPGD
Hydrochloric Acid SCHEMBL4581072 0.83 CCNC (0.50) KDM4ENPC1HPGDRAB9ACCNC
SCHEMBL4578262 0.82 LMNA (0.38) KDM4ENPC1TP53MAPTHPGD
SCHEMBL5148471 0.80 MKNK1 (0.36) KDM4ENPC1TP53MAPTHPGD
SCHEMBL4581556 0.77 CCNC (0.53) KDM4ENPC1MAPTHPGDRAB9A
SCHEMBL4581027 0.76 CCNC (0.44) PIM1CCNCCDK8MAPK14CYP46A1
SCHEMBL15743029 0.75 CNR1 (0.54) NPC1RAB9ACCNCCDK8CYP46A1
SCHEMBL4579596 0.75 ALDH1A1 (0.46) KDM4ENPC1TP53MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080032991-A1 2, 8-disubstituted Naphthyridine Derivatives SERENEX, INC. 2008-02-07 US disclosed
US-20080032991-A1 2, 8-disubstituted Naphthyridine Derivatives SERENEX, INC. 2008-02-07 US disclosed
US-20080032991-A1 2, 8-disubstituted Naphthyridine Derivatives SERENEX, INC. 2008-02-07 US disclosed
US-7282506-B2 2,8-disubstituted naphthyridine derivatives SERENEX, INC. (US) 2007-10-16 US disclosed
US-7282506-B2 2,8-disubstituted naphthyridine derivatives SERENEX, INC. (US) 2007-10-16 US disclosed
US-7282506-B2 2,8-disubstituted naphthyridine derivatives SERENEX, INC. (US) 2007-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080032991-A1 2, 8-disubstituted Naphthyridine Derivatives CCNA1, FOXM1, CCNA2 KDM4E 3744/4885NPC1 916/4885TP53 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.